Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502)

Running, not enrolling · Phase 4

Conditions studied: Duchenne Muscular Dystrophy

In brief

The VILT-502 study is Non-interventional Study(United States)/Low-intervention Clinical Trial (Canada) of Viltolarsen administered intravenously once weekly for 10 years to boys with DMD who complete the NS-065/NCNP-01-202 study.

Key facts

Study ID

NCT04687020

Run by

NS Pharma, Inc.

People needed

9

Starts

2021-06-10

Expected to finish

2032-10-01

Last updated by the study team

2022-10-19

Who can join

Age: any. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Patient, patient's parent or legal guardian have provided written informed consent/medical record release authorization prior to any extension study-specific procedures, and the patient has provided assent appropriate for his age and developmental status.
• Patient completed the NS-065/NCNP-01-202 study and was judged by the investigator as appropriate to participate in the VILT-502 study.
• Patient and parent or legal guardian are willing and able to comply with scheduled visits, study treatment administration plan, and study procedures.

You may not qualify if…

• Patient has an allergy or hypersensitivity to the study drug or to any of its constituents.
• Patient has severe behavioral or cognitive problems that preclude participation in the study, in the opinion of the investigator.
• Patient has previous or ongoing medical condition, medical history, physical findings or laboratory abnormalities that could affect safety, make it unlikely that treatment and observation will be correctly completed or impair the assessment of study results, in the opinion of the investigator.
• Patient had a treatment which was made for the purpose of dystrophin or its related protein induction after completing the NS-065/NCNP-01-202 study.
• Patient took any other investigational drugs after completing the NS-065/NCNP-01-202 study.
• Patient plans to participate in another clinical trial.
• Patient was judged by the investigator and/or the Sponsor as not appropriate to participate in the study for reasons other than #1 - #6 above.

Where it is running

• UC Davis — Sacramento, California, United States
• Lurie Children's Hospital — Chicago, Illinois, United States
• Duke University Medical Center — Durham, North Carolina, United States
• Children's Hospital of Richmond at VCU — Richmond, Virginia, United States
• Alberta Children's Hospital — Calgary, Alberta, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.